Atara Biotherapeutics Rises In Pre-market On Positive Phase 3 Trial Results Of Tab-cel

Shares of Atara Biotherapeutics, Inc. (ATRA), are trading 3 percent higher in pre-market on Tuesday after the company engaged in T-cell immunotherapy, announced efficacy and safety results from its study investigating tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease.

Tabelecleucel (tab-cel) is an off-the-shelf, allogeneic T-cell immunotherapy in development for the treatment of a type of cancer that may occur after a solid organ transplant (SOT) or allogeneic hematopoietic cell transplant (HCT).

The study revealed one-year survival rate of 89.2 percent for patients responding to Tab-cel Compared with 32.4 percent among non-responders. Safety was consistent with previously published data, and no new safety signals or concerns were reported.

Tab-cel's potential as a first-in-class treatment option for transplant recipients that develop EBV+ PTLD is validated by almost 90 percent of patients responding to treatment surviving after one year, and a similar two-year survival benefit of over 86 percent in patients who achieved a complete or partial response from Phase 2 and EAP studies.

Shares of Atara Biotherapeutics is currently trading in pre-market at $16.13, up $0.47 or 3 percent from previous close.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT